CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort

Affiliations

• ¹ Department of Neuropathology, Institute of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
• ² Department of Neurosurgery, University of Cologne Medical Center, Cologne, Germany.
• ³ Department of Pediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
• ⁴ Genome Informatics, Institute of Human Genetics, University of Duisburg-Essen, Essen, Germany.
• ⁵ Medical Systems Biology Division, Lübeck Institute of Experimental Dermatology and Institute for Cardiogenetics, University of Lübeck, Lübeck, Germany.
• ⁶ Department of Cell Biology (Tumor Research), University of Duisburg-Essen, Essen, Germany.
• ⁷ Institute of Diagnostic and Interventional Neuroradiology, University Hospital Würzburg, Würzburg, Germany.
• ⁸ Department of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany.
• ⁹ Westdeutsches Protonentherapiezentrum, Essen, Germany.
• ¹⁰ Division of Pediatric Hematology and Oncology, Department of Pediatrics, Obstetrics and Gynecology, University Hospital of Geneva, Geneva, Switzerland.
• ¹¹ Department of Neuropathology, Institute of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. t.pietsch@uni-bonn.de.